Esperion Therapeutics (NASDAQ:ESPR) was upgraded by equities research analysts at Bank of America from a “neutral” rating to a “buy” rating in a report released on Friday, January 5th, Marketbeat Ratings reports. The firm currently has a $76.00 target price on the biopharmaceutical company’s stock. Bank of America’s price target would indicate a potential upside of 3.74% from the company’s current price.
A number of other research firms have also recently commented on ESPR. Chardan Capital upped their price target on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the stock a “neutral” rating in a report on Wednesday, December 6th. BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, December 16th. Needham & Company LLC upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and increased their target price for the stock from $72.00 to $81.00 in a report on Thursday, December 14th. Stifel Nicolaus reiterated a “buy” rating and set a $70.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Finally, Northland Securities reiterated a “buy” rating and set a $72.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Six investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Esperion Therapeutics has a consensus rating of “Buy” and an average price target of $64.77.
Esperion Therapeutics (ESPR) traded up $3.35 during mid-day trading on Friday, reaching $73.26. 917,500 shares of the company’s stock were exchanged, compared to its average volume of 494,778. Esperion Therapeutics has a fifty-two week low of $10.71 and a fifty-two week high of $74.95. The company has a market capitalization of $1,880.00, a PE ratio of -10.68 and a beta of 2.73.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.07). During the same period in the previous year, the company posted ($0.77) EPS. sell-side analysts expect that Esperion Therapeutics will post -7.36 earnings per share for the current year.
In related news, Director Nicole Vitullo sold 9,326 shares of the stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the completion of the transaction, the director now directly owns 2,472 shares of the company’s stock, valued at approximately $133,117.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 32.50% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Meditor Group Ltd raised its position in shares of Esperion Therapeutics by 1.2% in the 4th quarter. Meditor Group Ltd now owns 2,322,835 shares of the biopharmaceutical company’s stock valued at $152,935,000 after purchasing an additional 27,900 shares during the last quarter. BB Biotech AG raised its position in shares of Esperion Therapeutics by 7.5% in the 2nd quarter. BB Biotech AG now owns 1,513,542 shares of the biopharmaceutical company’s stock valued at $70,047,000 after purchasing an additional 105,000 shares during the last quarter. State Street Corp raised its position in Esperion Therapeutics by 264.6% during the 2nd quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock worth $69,721,000 after buying an additional 1,093,292 shares during the last quarter. FMR LLC raised its position in Esperion Therapeutics by 2.3% during the 2nd quarter. FMR LLC now owns 1,338,588 shares of the biopharmaceutical company’s stock worth $61,950,000 after buying an additional 30,000 shares during the last quarter. Finally, Discovery Capital Management LLC CT raised its position in Esperion Therapeutics by 152.9% during the 2nd quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock worth $44,663,000 after buying an additional 583,529 shares during the last quarter. 92.35% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by Bank of America” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/16/esperion-therapeutics-espr-upgraded-to-buy-by-bank-of-america.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.